Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1534) 1534
Publication (144) 144
Book Review (15) 15
Magazine Article (4) 4
Book Chapter (2) 2
Newsletter (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1257) 1257
male (866) 866
ezetimibe (767) 767
index medicus (748) 748
azetidines - administration & dosage (720) 720
female (663) 663
azetidines - therapeutic use (645) 645
middle aged (495) 495
animals (444) 444
azetidines - pharmacology (437) 437
drug therapy, combination (383) 383
aged (373) 373
pharmacology & pharmacy (370) 370
anticholesteremic agents - administration & dosage (346) 346
adult (339) 339
anticholesteremic agents - therapeutic use (332) 332
treatment outcome (305) 305
azetidines - adverse effects (297) 297
hypercholesterolemia - drug therapy (274) 274
cholesterol, ldl - blood (264) 264
cholesterol (261) 261
simvastatin (252) 252
administration, oral (234) 234
azetidines - pharmacokinetics (210) 210
dose-response relationship, drug (209) 209
cardiac & cardiovascular systems (205) 205
benzylamines (198) 198
simvastatin - administration & dosage (192) 192
rats (189) 189
hypercholesterolemia (183) 183
double-blind method (182) 182
statins (175) 175
safety (170) 170
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (164) 164
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (161) 161
medicine, general & internal (158) 158
efficacy (154) 154
mice (154) 154
atorvastatin (152) 152
anticoagulants - therapeutic use (144) 144
peripheral vascular disease (144) 144
prevention (142) 142
simvastatin - therapeutic use (139) 139
drug therapy (137) 137
anticholesteremic agents - adverse effects (135) 135
ximelagatran (131) 131
anticholesteremic agents - pharmacology (129) 129
risk factors (127) 127
abridged index medicus (126) 126
thrombin - antagonists & inhibitors (123) 123
anticoagulants - administration & dosage (119) 119
cardiovascular (118) 118
atherosclerosis (114) 114
drug combinations (113) 113
time factors (113) 113
randomized controlled trials as topic (112) 112
research (111) 111
venous thromboembolism (111) 111
double-blind (109) 109
lipids (108) 108
hypercholesterolemia - blood (107) 107
primary hypercholesterolemia (107) 107
aged, 80 and over (103) 103
rats, sprague-dawley (102) 102
atorvastatin calcium (100) 100
care and treatment (100) 100
analysis (99) 99
clinical trials as topic (98) 98
low density lipoproteins (98) 98
pharmacokinetics (97) 97
warfarin (97) 97
cholesterol - blood (95) 95
melagatran (95) 95
hematology (92) 92
therapy (92) 92
adolescent (91) 91
coronary-heart-disease (91) 91
antilipemic agents (90) 90
triglycerides - blood (88) 88
pyrroles - administration & dosage (82) 82
dosage and administration (81) 81
cholesterol absorption inhibitor (80) 80
drug administration schedule (80) 80
medicine & public health (80) 80
young adult (80) 80
heptanoic acids - administration & dosage (79) 79
sulfonamides - administration & dosage (78) 78
glycine - analogs & derivatives (77) 77
metabolism (76) 76
anticoagulants - adverse effects (75) 75
drug interactions (75) 75
risk (75) 75
cholesterol, hdl - blood (74) 74
pharmacology/toxicology (74) 74
anticoagulants (73) 73
clinical trials (73) 73
direct thrombin inhibitor (73) 73
article (72) 72
azetidines - chemistry (72) 72
cardiovascular disease (72) 72
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1444) 1444
German (35) 35
Japanese (16) 16
French (12) 12
Spanish (11) 11
Hungarian (8) 8
Italian (6) 6
Russian (5) 5
Turkish (5) 5
Czech (4) 4
Danish (3) 3
Chinese (1) 1
Dutch (1) 1
Finnish (1) 1
Korean (1) 1
Lithuanian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia: The LAPLACE-2 Randomized Clinical Trial
by Robinson, Jennifer G and Nedergaard, Bettina S and Rogers, William J and Fialkow, Jonathan and Neutel, Joel M and Ramstad, David and Somaratne, Ransi and Legg, Jason C and Nelson, Patric and Scott, Rob and Wasserman, Scott M and Weiss, Robert and LAPLACE-2 Investigators
JAMA, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
IMPORTANCE In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE To... 
MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | EFFICACY | REDUCTION | SAFETY | TOLERABILITY | SUBTILISIN/KEXIN TYPE 9 | MONOCLONAL-ANTIBODY | SIMVASTATIN | AMG 145 | ATORVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Dyslipidemias - drug therapy | Double-Blind Method | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Humans | Middle Aged | Ezetimibe | Rosuvastatin Calcium | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Fluorobenzenes - administration & dosage | Hypercholesterolemia - drug therapy | Atorvastatin Calcium | Azetidines - therapeutic use | Pyrroles - administration & dosage | Anticholesteremic Agents - administration & dosage | Heptanoic Acids - administration & dosage | Female | Aged | Drug Therapy, Combination | Sulfonamides - administration & dosage | Clinical trials | Care and treatment | Pharmacology | Hypercholesterolemia | Research | Analysis | Side effects | Monoclonal antibodies | Drug therapy | Low density lipoprotein | Statins | Cholesterol | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis
by Robertson, Lindsay and Robertson, Lindsay and Kesteven, Patrick and Kesteven, Patrick and Mccaslin, James E and McCaslin, James E
The Cochrane database of systematic reviews, ISSN 1469-493X, 2015, Volume 2015, Issue 6, p. CD010956
Background Deep vein thrombosis (DVT) is a condition in which a clot forms in the deep veins, most commonly of the leg. It occurs in approximately 1 in 1,000... 
MEDICINE, GENERAL & INTERNAL | PULMONARY-EMBOLISM | EINSTEIN-DVT | DOUBLE-BLIND | EXTENDED TREATMENT | POOLED ANALYSIS | ACUTE VENOUS THROMBOEMBOLISM | DABIGATRAN VS. PLACEBO | STANDARD THERAPY | POSTTHROMBOTIC SYNDROME | SECONDARY PREVENTION | Dabigatran - administration & dosage | Pyridines - administration & dosage | Venous Thrombosis - drug therapy | Administration, Oral | Humans | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Benzylamines - administration & dosage | Rivaroxaban - administration & dosage | Factor Xa Inhibitors - administration & dosage | Randomized Controlled Trials as Topic | Pyridones - administration & dosage | Pyrazoles - administration & dosage | Azetidines - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis: A Randomized Trial
by Fiessinger, Jean-Noel and Huisman, Menno V and Davidson, Bruce L and Bounameaux, Henri and Francis, Charles W and Eriksson, Henry and Lundström, Torbjörn and Berkowitz, Scott D and Nyström, Per and Thorsén, Mona and Ginsberg, Jeffrey S and THRIVE Treatment Study Investigators, for the and THRIVE Treatment Study Investigato and THRIVE Treatment Study Investigators and Hjärt-kärlinstitutionen and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Cardiovascular Institute and Sahlgrenska Academy
JAMA, ISSN 0098-7484, 02/2005, Volume 293, Issue 6, pp. 681 - 689
CONTEXT Ximelagatran, an oral direct thrombin inhibitor with a rapid onset of action and predictable antithrombotic effect, has the potential to be a simple... 
ORAL XIMELAGATRAN | ENOXAPARIN | MEDICINE, GENERAL & INTERNAL | KNEE REPLACEMENT | THERAPY | VENOUS THROMBOEMBOLISM | MELAGATRAN | INTRAVENOUS UNFRACTIONATED HEPARIN | ABSORPTION | INHIBITOR XIMELAGATRAN | SECONDARY PREVENTION | Prodrugs - administration & dosage | Recurrence | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Venous Thrombosis - complications | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - administration & dosage | Warfarin - therapeutic use | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Pulmonary Embolism - complications | Double-Blind Method | Venous Thrombosis - drug therapy | Venous Thrombosis - mortality | Anticoagulants - therapeutic use | Treatment Outcome | Azetidines - administration & dosage | Azetidines - therapeutic use | Benzylamines | Aged | Prodrugs - therapeutic use | Alanine Transaminase - metabolism | Heparin, Low-Molecular-Weight - administration & dosage | Clinical trials | Cardiac arrhythmia | Thrombolytic drugs | Medical treatment | Blood clots | Low-Molecular-Weight/administration & dosage/therapeutic use | Anticoagulants/administration & dosage/therapeutic use | Pulmonary Embolism/complications | Drug Therapy | MEDICIN OCH HÄLSOVETENSKAP | Alanine Transaminase/metabolism | Warfarin/administration & dosage/therapeutic use | 80 and over | Azetidines/administration & dosage/therapeutic use | Combination | Prodrugs/administration & dosage/therapeutic use | Venous Thrombosis/complications/drug therapy/mortality | Heparin | MEDICAL AND HEALTH SCIENCES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
by Sanlorenzo, Martina, MD and Choudhry, Aditi, MD and Vujic, Igor, MD and Posch, Christian, MD and Chong, Kim, MD and Johnston, Katia, BSc and Meier, Melissa, MD and Osella-Abate, Simona, MSc and Quaglino, Pietro, MD and Daud, Adil, MD and Algazi, Alain, MD and Rappersberger, Klemens, MD and Ortiz-Urda, Susana, MD, PhD
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2014, Volume 71, Issue 6, pp. 1102 - 1109.e1
Background BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) frequently cause cutaneous adverse events. Objective We sought to investigate the cutaneous safety... 
Dermatology | cutaneous adverse event | rash | histology | inflammation | therapy | squamous cell carcinoma | squamous cell carcinoma therapy | ACTIVATION | IMPROVED SURVIVAL | OPEN-LABEL | DERMATOLOGY | METASTATIC MELANOMA | MEK INHIBITION | PATHWAY | RESISTANCE | RAF INHIBITORS | MUTATIONS | VEMURAFENIB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Skin Neoplasms - drug therapy | Follow-Up Studies | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Young Adult | Pyridones - administration & dosage | Carcinoma, Squamous Cell - mortality | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Retrospective Studies | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Kaplan-Meier Estimate | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Azetidines - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Indoles - adverse effects | Melanoma - drug therapy | Piperidines - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma - mortality | Complications and side effects | Medical colleges | Melanoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
by Larkin, James and Ascierto, Paolo A and Dréno, Brigitte and Atkinson, Victoria and Liszkay, Gabriella and Maio, Michele and Mandalà, Mario and Demidov, Lev and Stroyakovskiy, Daniil and Thomas, Luc and de la Cruz-Merino, Luis and Dutriaux, Caroline and Garbe, Claus and Sovak, Mika A and Chang, Ilsung and Choong, Nicholas and Hack, Stephen P and McArthur, Grant A and Ribas, Antoni
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 20, pp. 1867 - 1876
The combination of inhibitors to BRAF and MEK improved response rates and progression-free survival among patients with metastatic melanoma. Some toxicity was... 
METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | MULTICENTER | MEK INHIBITION | SAFETY | RAS MUTATIONS | RESISTANCE | IMPROVED SURVIVAL | OPEN-LABEL | ANTI-PD-1 | CANCER | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Indoles - administration & dosage | Melanoma - genetics | Adult | Female | MAP Kinase Kinase 1 - antagonists & inhibitors | Piperidines - administration & dosage | Azetidines - adverse effects | Kaplan-Meier Estimate | Survival Rate | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Azetidines - administration & dosage | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Aged | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Vemurafenib | Treatment outcome | Usage | Care and treatment | Analysis | Melanoma | Dosage and administration | Drug therapy, Combination | Risk factors | Chemotherapy | Toxicity | MEK inhibitors | Metastasis | Kinases | Survival | Metastases | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text 3‐Aminoazetidin‐2‐one Derivatives as N‐Acylethanolamine Acid Amidase (NAAA) Inhibitors Suitable for Systemic Administration
by Fiasella, Annalisa and Nuzzi, Andrea and Summa, Maria and Armirotti, Andrea and Tarozzo, Glauco and Tarzia, Giorgio and Mor, Marco and Bertozzi, Fabio and Bandiera, Tiziano and Piomelli, Daniele
ChemMedChem, ISSN 1860-7179, 07/2014, Volume 9, Issue 7, pp. 1602 - 1614
N‐Acylethanolamine acid amidase (NAAA) is a cysteine hydrolase that catalyzes the hydrolysis of endogenous lipid mediators such as palmitoylethanolamide (PEA).... 
inhibitors | β‐lactams | structure–activity relationships | cysteine hydrolase | N‐acylethanolamine acid amidase | β-lactams | structure-activity relationships | N-acylethanolamine acid amidase | PALMITOYLETHANOLAMIDE | CHEMISTRY, MEDICINAL | PROTEOLYTIC ACTIVATION | HYDROLASE | beta-lactams | ACTIVATED-RECEPTOR-ALPHA | PEPTIDES | CERAMIDASE | INFLAMMATION | ESTERS | PHARMACOLOGY & PHARMACY | DI(2-PYRIDYL) CARBONATE | REVEALS | Amidohydrolases - metabolism | Humans | Half-Life | Rats | Amidohydrolases - antagonists & inhibitors | Azetidines - pharmacokinetics | Structure-Activity Relationship | Enzyme Inhibitors - chemical synthesis | Azetidines - chemistry | Animals | Enzyme Inhibitors - pharmacokinetics | Enzyme Inhibitors - chemistry | Protein Binding | Azetidines - chemical synthesis | Mice | Cysteine | Neurophysiology | structure-activity relationship | stability | NAAA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
by Bays, Harold and Gaudet, Daniel and Weiss, Robert and Ruiz, Juan Lima and Watts, Gerald F and Gouni-Berthold, Ioanna and Robinson, Jennifer and Zhao, Jian and Hanotin, Corinne and Donahue, Stephen
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 08/2015, Volume 100, Issue 8, pp. 3140 - 3148
Context: Despite current standard of care, many patients at high risk of cardiovascular disease (CVD) still have elevated low-density lipoprotein cholesterol... 
DENSITY-LIPOPROTEIN CHOLESTEROL | THERAPY | METAANALYSIS | EFFICACY | SAFETY | ENDOCRINOLOGY & METABOLISM | PCSK9 | MONOCLONAL-ANTIBODY | HYPERCHOLESTEROLEMIA | EZETIMIBE | ROSUVASTATIN | Azetidines - immunology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Ezetimibe | Male | Heptanoic Acids - adverse effects | Pyrroles - immunology | Pyrroles - administration & dosage | Cardiovascular Diseases - blood | Heptanoic Acids - administration & dosage | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Drug Therapy, Combination | Antibodies, Monoclonal - immunology | Azetidines - adverse effects | Treatment Outcome | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - immunology | Atorvastatin Calcium | Heptanoic Acids - immunology | Azetidines - administration & dosage | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Antibodies - blood | Aged | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
by Keystone, Edward C and Taylor, Peter C and Drescher, Edit and Schlichting, Douglas E and Beattie, Scott D and Berclaz, Pierre-Yves and Lee, Chin H and Fidelus-Gort, Rosanne K and Luchi, Monica E and Rooney, Terence P and Macias, William L and Genovese, Mark C
Annals of the Rheumatic Diseases, ISSN 0003-4967, 02/2015, Volume 74, Issue 2, pp. 333 - 340
Objectives To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid... 
CRITERIA | PLACEBO | DISEASE | STATS | IMPROVEMENT | TOFACITINIB | RHEUMATOLOGY | VALIDITY | JAKS | Enzyme Inhibitors - adverse effects | Double-Blind Method | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Azetidines - adverse effects | Male | Methotrexate - therapeutic use | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Azetidines - administration & dosage | Arthritis, Rheumatoid - drug therapy | Antirheumatic Agents - adverse effects | Sulfonamides - adverse effects | Female | Immunosuppressive Agents - adverse effects | Immunosuppressive Agents - administration & dosage | Sulfonamides - administration & dosage | Treatment outcome | Safety and security measures | Rheumatoid arthritis | Analysis | Dosage and administration | Drug therapy | Methotrexate | Patients | Health aspects | Tuberculosis | Cytokines | Laboratories | Drug dosages | Manuscripts | DMARDs (biologic) | Clinical and Epidemiological Research | Inflammation | Rheumatoid Arthritis | 1506
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study
by Ribas, A and Gonzalez, R and Pavlick, A and Hamid, O and Gajewski, TF and Daud, A and Flaherty, L and Logan, T and Chmielowski, B and Lewis, K and Kee, D and Boasberg, P and Yin, M and Chan, I and Musib, L and Choong, N and Puzanov, I and McArthur, GA
LANCET ONCOLOGY, ISSN 1470-2045, 08/2014, Volume 15, Issue 9, pp. 954 - 965
Background Addition of a MEK inhibitor to a BRAF inhibitor enhances tumour growth inhibition, delays acquired resistance, and abrogates paradoxical activation... 
DABRAFENIB | METASTATIC MELANOMA | BRAF INHIBITOR | MEK INHIBITION | ONCOLOGY | ACQUIRED-RESISTANCE | IMPROVED SURVIVAL | OPEN-LABEL | MUTATIONS | Prospective Studies | Skin Neoplasms - drug therapy | Follow-Up Studies | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Patient Selection | Dose-Response Relationship, Drug | Melanoma - genetics | Neoplasm Invasiveness - pathology | Skin Neoplasms - mortality | Adult | Female | Drug Therapy, Combination | Skin Neoplasms - pathology | Piperidines - administration & dosage | Drug Administration Schedule | Risk Assessment | Azetidines - adverse effects | Survival Rate | Treatment Outcome | Melanoma - pathology | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - drug effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Aged | Infusions, Intravenous | Mutation | Neoplasm Staging | Sulfonamides - administration & dosage | Melanoma - mortality | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Management of Treatment‐Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
by Daud, Adil and Tsai, Katy
The Oncologist, ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
Tremendous progress has been made in the clinical landscape of advanced‐stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | IMPROVED SURVIVAL | PHASE-3 | COMBINATION | COMBINED DABRAFENIB | THERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | BRAF-MUTANT MELANOMA | VEMURAFENIB | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma and Cutaneous Malignancies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)
by Cohen Aubart, Fleur and Emile, Jean-François and Carrat, Fabrice and Charlotte, Frédéric and Benameur, Neila and Donadieu, Jean and Maksud, Philippe and Idbaih, Ahmed and Barete, Stéphane and Hoang-Xuan, Khê and Amoura, Zahir and Haroche, Julien
Blood, ISSN 0006-4971, 09/2017, Volume 130, Issue 11, pp. 1377 - 1380
MELANOMA | EFFICACY | MUTATIONS | HEMATOLOGY | CELL-FREE DNA | VEMURAFENIB | HISTIOCYTOSES | Erdheim-Chester Disease - diagnostic imaging | Follow-Up Studies | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Oximes - therapeutic use | Molecular Targeted Therapy | Indoles - administration & dosage | Multicenter Studies as Topic | Registries | Retrospective Studies | Imidazoles - therapeutic use | France | Erdheim-Chester Disease - genetics | Piperidines - administration & dosage | Drug Administration Schedule | Treatment Outcome | Positron Emission Tomography Computed Tomography | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Erdheim-Chester Disease - drug therapy | Azetidines - administration & dosage | Azetidines - therapeutic use | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Indoles - therapeutic use | Sulfonamides - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration - HEAVEN Study
by Kovarnik, Tomas and Mintz, Gary S and Skalicka, Hana and Kral, Ales and Horak, Jan and Skulec, Roman and Uhrova, Jana and Martasek, Pavel and Downe, Richard W and Wahle, Andreas and Sonka, Milan and Mrazek, Vratislav and Aschermann, Michael and Linhart, Ales
Circulation Journal, ISSN 1346-9843, 2012, Volume 76, Issue 1, pp. 176 - 183
Background: There is no study focusing on changes in coronary atherosclerosis during dual lipid-lowering therapy with statin and ezetimibe. Methods and... 
Intravascular ultrasound | Statins | Atherosclerosis | Plaque | INTRAVASCULAR ULTRASOUND ANALYSIS | C-REACTIVE PROTEIN | CARDIAC & CARDIOVASCULAR SYSTEMS | LUMEN SIZE | LIPID-LOWERING THERAPY | PLAQUE COMPOSITION | EXPERT CONSENSUS DOCUMENT | IN-VIVO | APOE-DEFICIENT MICE | CORONARY-ARTERY-DISEASE | PROGRESSION | Coronary Vessels - diagnostic imaging | Single-Blind Method | Plaque, Atherosclerotic - diagnostic imaging | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Ezetimibe | Ultrasonography, Interventional | Male | Coronary Vessels - metabolism | Coronary Artery Disease - pathology | Lipoproteins - metabolism | Female | Drug Therapy, Combination | Plaque, Atherosclerotic - pathology | Pyrroles - therapeutic use | Coronary Vessels - pathology | Treatment Outcome | Coronary Artery Disease - drug therapy | Cholesterol - metabolism | Cell Adhesion Molecules - metabolism | Disease Progression | Coronary Artery Disease - diagnostic imaging | Anticholesteremic Agents - therapeutic use | Azetidines - therapeutic use | Atorvastatin | Aged | Plaque, Atherosclerotic - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: Evidence from a rat model of nicotine self-administration
by Liu, Xiu
Psychopharmacology, ISSN 0033-3158, 11/2013, Volume 230, Issue 2, pp. 203 - 213
The α4β2 subtype of nicotinic acetylcholine receptors (nAChRs) plays a central role in the mediation of nicotine reinforcement. Positive allosteric modulators... 
Desformylflustrabromine | Self-administration | Nicotinic acetylcholine receptors (nAChRs) | Galantamine | Positive allosteric modulator | 5-Iodo-A-85380 | Nicotine | Allosteric Regulation - drug effects | Nicotine - administration & dosage | Receptors, Nicotinic - metabolism | Pyridines - administration & dosage | Rats | Male | Tobacco Use Disorder - drug therapy | Galantamine - administration & dosage | Azetidines - pharmacology | Indole Alkaloids - administration & dosage | Hydrocarbons, Brominated - pharmacology | Rats, Sprague-Dawley | Smoking Cessation - methods | Smoking Prevention | Galantamine - pharmacology | Dose-Response Relationship, Drug | Reinforcement Schedule | Self Administration | Animals | Azetidines - administration & dosage | Indole Alkaloids - pharmacology | Hydrocarbons, Brominated - administration & dosage | Pyridines - pharmacology | nicotine | nicotinic acetylcholine receptors (nAChRs) | self-administration | 5-iodo-A-85380 | desformylflustrabromine | galantamine | positive allosteric modulator
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights